These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29119713)

  • 1. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
    Currie CJ; Holden SE; Jenkins-Jones S; Morgan CL; Voss B; Rajpathak SN; Alemayehu B; Peters JR; Engel SS
    Diabetes Obes Metab; 2018 Apr; 20(4):821-830. PubMed ID: 29119713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study.
    Zaccardi F; Ling S; Lawson C; Davies MJ; Khunti K
    Diabetologia; 2020 Oct; 63(10):2129-2139. PubMed ID: 32728893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
    Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME
    BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.
    Currie CJ; Peters JR; Tynan A; Evans M; Heine RJ; Bracco OL; Zagar T; Poole CD
    Lancet; 2010 Feb; 375(9713):481-9. PubMed ID: 20110121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.
    Ekström N; Miftaraj M; Svensson AM; Andersson Sundell K; Cederholm J; Zethelius B; Gudbjörnsdottir S; Eliasson B
    Diabetes Obes Metab; 2012 Aug; 14(8):717-26. PubMed ID: 22364580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
    Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
    Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
    Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
    Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management.
    International Hypoglycaemia Study Group
    Lancet Diabetes Endocrinol; 2019 May; 7(5):385-396. PubMed ID: 30926258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
    Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
    Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
    van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
    Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication.
    Jung HH; Lee S
    Diabetes Obes Metab; 2020 Feb; 22(2):243-253. PubMed ID: 31602755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
    Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
    Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.